Cara Therapeutics, Inc. stock is up 60.89% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 February’s closed higher than January.
Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!